ライフサイエンスコーパス: diabetic patient

1 s a main cause of heart failure and death in diabetic patients.

2 ed to reduce cardiovascular complications in diabetic patients.

3 evalence of Kaposi's sarcoma (KS) is seen in diabetic patients.

4 ge of risk for adverse outcomes after AMI in diabetic patients.

5 otential therapy to improve wound healing in diabetic patients.

6 observed in hyperglycemic Akita mice and in diabetic patients.

7 non-diabetic and clinically diagnosed type 2 diabetic patients.

8 ting the expansion of residual beta cells in diabetic patients.

9 ed therapeutics of critical limb ischemia in diabetic patients.

10 ction and grading of coronary lesions in non-diabetic patients.

11 d lipid control and cardiovascular events in diabetic patients.

12 lls represent potential new therapeutics for diabetic patients.

13 hat is elevated in the serum and vitreous of diabetic patients.

14 ions on a number of proteins are elevated in diabetic patients.

15 velopment of cardiovascular complications in diabetic patients.

16 ge and vision loss in nondiabetic as well as diabetic patients.

17 bese/T2D mice that was comparable to that of diabetic patients.

18 DR and risk factors associated with it among diabetic patients.

19 including for the increasing number of obese diabetic patients.

20 ores of the heels often lead to limb loss in diabetic patients.

21 dysregulation was detected in platelets from diabetic patients.

22 ioside, making this formulation suitable for diabetic patients.

23 ially reduce the cerebral ischemic injury in diabetic patients.

24 plicated cataract surgery in nondiabetic and diabetic patients.

25 f acute chest pain of coronary origin in non-diabetic patients.

26 of diabetes based on serum insulin levels in diabetic patients.

27 s in glucose and energy homeostasis in obese diabetic patients.

28 on of a GABAA-R PAM reducing HbA1c levels in diabetic patients.

29 es micro- and macrovascular complications in diabetic patients.

30 rm improvement of glycemic control in type 2 diabetic patients.

31 ep disorders and congestive heart failure in diabetic patients.

32 sus no surgical treatment for severely obese diabetic patients.

33 rgeted therapies to promote wound healing in diabetic patients.

34 eta3 for treating corneal and skin wounds in diabetic patients.

35 y ameliorate the wound-healing deficiency in diabetic patients.

36 y of Mycobacterium tuberculosis infection in diabetic patients.

37 caemic control and low hypoglycaemic risk in diabetic patients.

38 s in these cells have been well described in diabetic patients.

39 ove glycemic regulation in insulin-dependent diabetic patients.

40 erse alterations in human CMSC obtained from diabetic patients.

41 APOO), which is overexpressed in hearts from diabetic patients.

42 tion in the rate of dermal tissue growth for diabetic patients.

43 ion between metformin use and cancer risk in diabetic patients.

44 etinal vascular leakage and proliferation in diabetic patients.

45 nd toward higher filling pressures (E/e') in diabetic patients.

46 with RNFL and macular thickness among type 2 diabetic patients.

47 alternative to blood glucose monitoring for diabetic patients.

48 eutic approach to treat beta-cell failure in diabetic patients.

49 ower risks of lung and respiratory cancer in diabetic patients.

50 t not Ca(2+) sparks were lower in cells from diabetic patients.

51 agnosis using a gold standard method for 346 diabetic patients.

52 lar thickness with serum uric acid in type 2 diabetic patients.

53 es, and this is compromised in arteries from diabetic patients.

54 he treatment efficacy and life qualities for diabetic patients.

55 es occurring in approximately 15% of chronic diabetic patients.

56 nifestations is of substantial importance to diabetic patients.

57 -diabetics and 18 were more common in type-1 diabetic patients.

58 h further reduces potential complications in diabetic patients.

59 e risk of myocardial infarction or stroke in diabetic patients.

60 c neuropathy affects the majority of type II diabetic patients.

61 ization in retinopathy of prematurity and in diabetic patients.

62 isk factors related to ophthalmoplegia among diabetic patients.

63 antation is a promising treatment for type 1 diabetic patients.

64 of hyperglycaemia, and in islets from type-2 diabetic patients.

65 iabetic health education and promotion among diabetic patients.

66 compared with SC-beta cells derived from non-diabetic patients.

67 gy and risk factors of ophthalmoplegia among diabetic patients.

68 insulinomas and imaging of beta-cell mass in diabetic patients.

69 eported a higher prevalence of classic KS in diabetic patients.

70 e effective treatments for chronic wounds in diabetic patients.

71 10-4.23; P = 0.03) of elevated NO2 levels in diabetic patients.

72 s more than twice as high in T2D than in non-diabetics patients.

73 Two hundred twenty-four asymptomatic diabetic patients (121 men; mean patient age, 61.8 years

74 2016, which analyzed 41 eyes with DR from 31 diabetic patients, 20 eyes without DR from 11 diabetic p

75 The study included 13 eyes of 9 diabetic patients (4 men and 5 women aged 34-58 years) w

76 3 large cohorts: (1) 159,000 severely obese diabetic patients (4185 had bariatric surgery) from 3 HM

77 eased by more than two fold (P<0.001) in the diabetic patients (5.56+/-0.73 ng/mL) as compared to the

78 Fifty-six diabetic patients (88 eyes) and 11 healthy nondiabetic c

79 In a safety cohort of critically ill diabetic patients, a blood glucose concentration target

80 n to estimate the rate of ischemic stroke in diabetic patients according to time-varying measures of

81 partly explain the poor prognosis of type 2 diabetic patients after myocardial infarction.

82 low-up and the reasons for poor follow-up of diabetic patients after screening for retinopathy in Kil

83 A total of 64,351 Saudi diabetic patients aged more than 18 years and registered

84 Among diabetic patients, all-cause mortality at 1 year was 18.

85 .1%; HR, 1.30; 95% CI, 0.49-3.41; P=0.60 for diabetic patients and 2.4% versus 3.4%; HR, 0.70; 95% CI

86 Sequential NAION occurred in 36.8% of diabetic patients and 20.9% of nondiabetic patients.

87 imaging of foot arteries was conducted in 37 diabetic patients and 36 non-diabetic subjects to determ

88 median follow-up duration was 38.7 weeks in diabetic patients and 52.9 weeks in nondiabetic patients

89 specimens from the distal leg from 96 type 2 diabetic patients and 75 healthy control subjects were u

90 of IAPP and Abeta in islet amyloid in type 2 diabetic patients and Abeta deposits in brains of patien

91 d glycation end products (AGE) accumulate in diabetic patients and aging people because of high amoun

92 g cause of morbidity and mortality among the diabetic patients and currently there is no effective me

93 In diabetic patients and diabetic mouse models (streptozoto

94 s well as a proof-of-concept study in type 1 diabetic patients and healthy subjects showed a direct c

95 fractal dimension of retinal vasculature of diabetic patients and healthy subjects, even when there

96 Although it has been observed in diabetic patients and in animal models of DR, the cause

97 In diabetic patients and in patients with coronary artery d

98 e provide evidence in both vitreous humor of diabetic patients and in retina of a murine model of dia

99 t at elevated levels in blood and tissues of diabetic patients and is thought to contribute to diabet

100 gnificantly up-regulated in the glomeruli of diabetic patients and mice, suggesting induction of the

101 shown to convey anti-inflammatory effects in diabetic patients and nephroprotection in rodent models

102 n be useful to follow the visual function of diabetic patients and should be used together to discrim

103 d to screen fundus photographs obtained from diabetic patients and to identify, with high reliability

104 erstanding the complex pathogenesis of TB in diabetic patients and to test new strategies to improve

105 on, we resequenced a 455-kb region in type 1 diabetic patients and unaffected control subjects, ident

106 iabetic patients, 20 eyes without DR from 11 diabetic patients, and 16 eyes from 12 healthy age-match

107 d RyR2-expressing mice, in human islets from diabetic patients, and in an established murine model of

108 n older patients, African American patients, diabetic patients, and those who arrived by ambulance, a

109 Diabetic patients are at increased risk for future cardi

110 including death and recurrent ischemia, some diabetic patients are likely at low risk, whereas others

111 scatheter aortic valve replacement (TAVR) in diabetic patients are limited by small sample size and c

112 Diabetic patients are more susceptible to the developmen

113 the onset and progression of nephropathy in diabetic patients are not fully elucidated.

114 fter an acute myocardial infarction (AMI) in diabetic patients are unknown.

115 Blood samples were taken from uncontrolled diabetic patients as well as age-, gender-, and body-mas

116 he odds of developing CME in nondiabetic and diabetic patients, as compared to topical corticosteroid

117 A phase IIb study conducted among diabetic patients at high vascular risk indicates that c

118 progression in high-risk subjects and type 1 diabetic patients at onset and at 12 and 24 months after

119 DZX should be avoided in diabetic patients at risk of ischemic events.

120 hat the ocular knowledge and practices among diabetic patients attending a tertiary-care hospital in

121 ld be more effective in treating early-stage diabetic patients before they develop severe beta cell d

122 In asymptomatic diabetic patients, BMI was the primary modifiable risk f

123 and contractile dysfunction are observed in diabetic patients but not in "metabolically healthy" obe

124 aintenance are often impaired in the skin of diabetic patients, but the pathogenesis has not been wel

125 f disruption of the photoreceptors on OCT in diabetic patients can be a manifestation of underlying c

126 Macular ischemia in diabetic patients can be associated with photoreceptor c

127 Two families and the diabetic patient carried the nonsense c.6814G>T (p.Glu22

128 nd elevated glycated hemoglobin in obese and diabetic patients.CCK responsiveness varies widely acros

129 Ile were more abundant in the scalp hair of diabetic patients compared to the hair of control subjec

130 ogical tests in 86 recently diagnosed type 2 diabetic patients compared with 48 control subjects.

131 e results suggest that high blood glucose in diabetic patients contributes to development of KS by pr

132 ssion and regulation in kidney biopsies from diabetic patients, cultured human podocytes, and a novel

133 ined from normoglycemic (ND-CMSC) and type 2 diabetic patients (D-CMSC), identifying the histone acet

134 unds are one of the major health problems in diabetic patients, D1 dopamine receptor agonists, which

135 nal thoracic artery graft is advantageous in diabetic patients despite higher risk of sternal wound c

136 tion of the DMN during recognition in type 2 diabetic patients, despite normal cognition.

137 lly observed for persistent complications in diabetic patients, despite subsequent glycemic control.

138 enetic explanation for the increased risk of diabetic patients developing dementia.

139 Diabetic patients diagnosed with cirrhosis between 2000

140 oxolone failed in clinical studies in type 2 diabetic patients due to cardiovascular side effects.

141 d to clinically improve glucose tolerance in diabetic patients due to its ability to enhance insulin

142 delivery systems in protecting the health of diabetic patients during times of economic stress.

143 Surprisingly, about 35% of diabetic patients either lack or have a delayed response

144 Diabetic patients exhibit a reduction in beta cells, whi

145 Ten (35.71%) diabetic patients exhibited lens opacification.

146 Compared with control subjects, diabetic patients exhibited significantly reduced cornea

147 Diabetic patients experience functional deficits in dark

148 Overall diabetic patients experienced a significantly higher ris

149 r the accurate pharmacokinetic monitoring of diabetic patients, for sport antidoping and forensic tox

150 This cross-sectional study included 122 diabetic patients from the outpatient department (OPD) o

151 existing clinical markers in differentiating diabetic patients from their healthy counterparts.

152 nd eye screenings were carried out among 625 diabetic patients from urban and rural areas of Gegharku

153 ifferent from nondiabetic controls, although diabetic patients had a higher prevalence of cardiovascu

154 At baseline, diabetic patients had a significant neuropathy compared

155 Diabetic patients had lower PSV and higher RI within CRA

156 Diabetic patients had more ventricular hypertrophy, but

157 vention Triage Strategy (ACUITY) trial, 1772 diabetic patients had multivessel disease with left ante

158 Diabetic patients had worse maximal (peak oxygen uptake)

159 Diabetic patients have a greater risk of nonarteritic an

160 Diabetic patients have a twofold to fourfold increased r

161 Type II diabetic patients have elevated O-GlcNAc-modified protei

162 mmended period, however less than 75% of pre-diabetic patients have repeated tests within the suggest

163 We show that diabetic patients have substantial levels of preexisting

164 onducted a retrospective cohort study of 819 diabetic patients hospitalized for treatment of 1212 uni

165 In diabetic patients, impaired wound healing is one of the

166 The frequency of DR may be high among diabetic patients in Cameroon.

167 ge and the risk of Parkinson disease (PD) in diabetic patients in Taiwan.

168 primate and pivotal clinical trials in human diabetic patients in the near future.

169 There were 2,101 diabetic patients included in the duration analysis: 40%

170 Among 1,933 diabetic patients included in the HbA1c analysis, 46% ha

171 Nitrotyrosine levels were higher in diabetic patients, indicating endothelial oxidative stre

172 stent PKCdelta elevation in fibroblasts from diabetic patients inhibits insulin signaling and functio

173 Among diabetic patients, intracoronary versus intravenous abci

174 The optimal revascularization technique in diabetic patients is an important unresolved question.

175 orming retinal screening examinations on all diabetic patients is an unmet need, and there are many u

176 ated level of von Willebrand factor (VWF) in diabetic patients is associated with increased risk of t

177 ce over a 28 day implant period in 12 type 1 diabetic patients is reported.

178 6 (SIRT6) in atherosclerotic progression of diabetic patients is unknown.

179 liva and blood of healthy individuals and in diabetic patients it was nearly in the order of 0.95, th

180 For diabetic patients, many of these processes are compromis

181 evated circulating antiangiogenic serpins in diabetic patients may contribute to impaired wound heali

182 ased levels of this sphingolipid observed in diabetic patients may contribute to the reduced function

183 female patients), 20 eyes without DR from 11 diabetic patients (mean [SD] age, 58.8 [10.1] years; 5 w

184 This study included 41 eyes with DR from 31 diabetic patients (mean [SD] age, 62.8 [13.4] years; 12

185 s are significantly higher in the nonsmoking diabetic patients (n = 12) than in normal nonsmoking sub

186 hionine residues are significantly higher in diabetic patients (n = 19) than in nondiabetic individua

187 Diabetic patients (n = 300) were recruited at the ophtha

188 as no effect on GLP-1 RA treatment in type 2 diabetic patients (n = 527).

189 Macular vessels from diabetic patients (n=7) showed significantly more VEGFR-

190 or for NAION was hyperlipidemia (62.9%); for diabetic patients, NAION risk factors included hypertens

191 eric-Coated and Immediate Release Aspirin in Diabetic Patients; NCT01515657).

192 ulating insulin secretion from beta-cells in diabetic patients, no pharmacological agents have been d

193 onist did not improve the remission rates of diabetic patients not taking insulin as part of their ph

194 ocular knowledge and practices among Type 2 diabetic patients of Bangladesh.

195 Since elderly type 2 diabetic patients often demonstrate cognitive impairment

196 lipidemia often develop type 2 diabetes, and diabetic patients often have dyslipidemia.

197 Because diabetic patients often have hyperglucagonemia, AMPKalph

198 In study 2, aldosterone was measured in diabetic patients on a high-sodium diet, before and afte

199 nondiabetic (OR 0.21; 95% CI 0.10-0.44) and diabetic patients (OR 0.17; 95% CI 0.05-0.50).

200 of circulating NAMPT are found in obese and diabetic patients, our data could also explain the incre

201 pe I, and endothelin-1 levels were higher in diabetic patients (p < 0.05 for all).

202 th those of nondiabetic or controlled type 2 diabetic patients (P<0.05).

203 proliferative processes in restenosis-prone diabetic patients, particularly those patients in whom s

204 tivated from biopsy material obtained from a diabetic patient presenting with complaints of headache

205 full high cholesterol in 2-3 years, and pre-diabetic patients progress to full diabetes in 1-2 years

206 rimary endpoint was significantly reduced in diabetic patients randomized to intracoronary abciximab

207 ge index was significantly increased only in diabetic patients randomized to intracoronary compared w

208 All diabetic patients referred to a tertiary ophthalmology h

209 Diabetes Registry (SNDR) database to select diabetic patients regardless of their diabetes type.

210 w the 2.5th percentile in 21% and 14% of the diabetic patients, respectively.

211 Data were collected from 23 lesions from 8 diabetic patients, seen from July 2012 through October 2

212 We examined whether middle-aged type 2 diabetic patients show reduced white matter integrity in

213 We investigated whether middle-aged type 2 diabetic patients show these brain activity patterns dur

214 Diabetic patients showed lower fractional anisotropy (FA

215 dict long term, AGE-related complications in diabetic patients, such as impaired vision, increased ar

216 A large proportion of diabetic patients suffer from severe complications such

217 generate the first SC-beta cells from type 1 diabetic patients (T1D).

218 Bilateral injections were more frequent in diabetic patients than in nAMD patients (respectively 48

219 or B and T cell responses to IA-2 in HLA-DR4 diabetic patients that may explain HLA associations of I

220 In diabetic patients the benefit was more extreme, with a 4

221 In the diabetic patients the level of glucose must be determine

222 Among diabetic patients, the 1-year rates of stroke were simil

223 In diabetic patients, the overall vascular diameter and wal

224 In Taiwanese diabetic patients, the risk of PD is lower in statin use

225 In diabetic patients, there was significantly increased ris

226 tial to restore the beta-cell compartment in diabetic patients, thereby overcoming the inadequacies o

227 nnel function in vascular smooth muscle from diabetic patients through unique mechanisms, which may c

228 a longitudinal study involving obese type 2 diabetic patients treated for 1 year with GLP-1R agonist

229 he BIOSCIENCE trial, clinical outcomes among diabetic patients treated with BP-SES or DP-EES were com

230 nical and therapeutic implications, e.g., in diabetic patients treated with high doses of insulin.

231 VP1 was detected in the islets of all type 1 diabetic patients (two of nine controls).

232 1R2 levels increased significantly in type 2 diabetic patients under the same conditions (+6.9 x 10(5

233 lucose regimen improves metabolic control in diabetic patients undergoing peritoneal dialysis.

234 The prevalence of PVD among nondiabetic and diabetic patients was 4.5% and 25.3% (P < 0.0001).

235 The fibrinogen glycation of the diabetic patients was reduced from 8.8 to 5.0 mol glucos

236 minantly new-generation drug-eluting stents, diabetic patients were at increased risk for repeat targ

237 Overall, 6600 of the diabetic patients were insulin treated (IT).

238 Diabetic patients were more likely to have been hospital

239 A total of 180 diabetic patients were recruited (90 patients with no di

240 Diabetic patients were screened by diagnosis of Internat

241 P/Rep atrial tissue from uncontrolled type 2 diabetic patients were significantly increased compared

242 Twenty-two diabetic patients were treated with drugs that work on t

243 75 137 publicly available fundus images from diabetic patients were used to train and test an artific

244 f enterovirus in pancreatic islets of type 1 diabetic patients, which is consistent with the possibil

245 the example of revascularization choices for diabetic patients who have multivessel coronary artery d

246 upillary light reflex (PLR) abnormalities in diabetic patients who have non-proliferative diabetic re

247 A total of 295 diabetic patients who lacked sensitivity to a monofilame

248 aluated major cardiovascular outcomes in all diabetic patients who underwent coronary revascularizati

249 We included all diabetic patients who were referred from diabetes clinic

250 ce, which suggests a therapeutic strategy in diabetic patients, who remain at elevated cardiovascular

251 This is particularly true for diabetic patients, who tend to develop chronic skin woun

252 ersus 0.9%; P<0.0001); it failed to do so in diabetic patients with (5.7% versus 5.8%; P=0.89) or wit

253 eight randomized trials that enrolled 24 015 diabetic patients with a total of 71 595 patient-years o

254 n (CABG vs. PCI with drug-eluting stents) in diabetic patients with ACS and MV-CAD.

255 In the large-scale ACUITY trial, diabetic patients with acute coronary syndrome and multi

256 The preferred revascularization strategy for diabetic patients with acute coronary syndromes and mult

257 globin A1c (HbA1c) with risk of stroke among diabetic patients with AF.

258 tional rationale for the treatment of type 2 diabetic patients with an IL-1beta antagonist.

259 Results Between diabetic patients with and diabetic patients without DPN

260 lacement (AVR) improves clinical outcomes in diabetic patients with aortic stenosis (AS).

261 has been proposed as a treatment option for diabetic patients with BMI less than 35 kg/m2 but the ef

262 hese therapeutic agents for the treatment of diabetic patients with cardiovascular disease.

263 as during spontaneous hypoglycemia in type 2 diabetic patients with cardiovascular risk.

264 Metformin should therefore be continued in diabetic patients with cirrhosis if there is no specific

265 creas transplant alone is utilized rarely in diabetic patients with compensated renal function.

266 sty (PTA) for the reduction of restenosis in diabetic patients with critical limb ischemia undergoing

267 giogenic activities, were elevated in type 2 diabetic patients with diabetic vascular complications.

268 Firstly, a comparative study of diabetic patients with different grades of DR.

269 The study included 20 diabetic patients with DPN (10 men, 10 women), 20 diabet

270 reas transplant is a potential treatment for diabetic patients with end-organ complications.

271 er healing and address MRSA into the care of diabetic patients with foot ulcers.

272 ve glucose biosensor, which is important for diabetic patients with frequent/continuous glucose monit

273 aims to restore physiologic normoglycemia in diabetic patients with glomerulopathy and avoid or delay

274 ate markers of cardiovascular disease in non-diabetic patients with high cardiovascular risk, taking

275 se data hold promise for treatment of type 1 diabetic patients with IL-1beta blockade combined with a

276 We evaluated the outcomes of diabetic patients with moderate and high-risk acute coro

277 mptying (GE) in a 12-week, phase 2B study of diabetic patients with moderate to severe gastroparesis

278 percutaneous coronary intervention (PCI) in diabetic patients with multivessel coronary artery disea

279 In diabetic patients with MV-CAD, CABG was associated with

280 rcise or increased fibre-intake alone in pre-diabetic patients with NAFLD.

281 VA at presentation and at final follow-up in diabetic patients with NAION were not significantly diff

282 ed the occurrence of diabetic foot ulcers in diabetic patients with neuropathy.

283 f DN patients (macroalbuminuric, n = 121) to diabetic patients with no evidence of DN (normoalbuminur

284 (HFC) and increase glycaemic control in pre-diabetic patients with non-alcoholic fatty liver disease

285 ional study addressed this problem in type 1 diabetic patients with normal ocular fundus and absent b

286 ictive study, RVG features were analysed for diabetic patients with progressive DR over 7 years.

287 In a longitudinal study of 38 obese diabetic patients with RYGB, we found higher baseline st

288 In diabetic patients with STEMI, the administration of intr

289 n rate and the composition of RSSC in type-1 diabetic patients with those in matched controls in orde

290 revention of Cardiovascular Complications in Diabetic Patients With Vitamin E Treatment) study, with

291 Thirty-nine eyes of 39 diabetic patients without clinical evidence of diabetic

292 dal thickness (CT) and all retinal layers of diabetic patients without diabetic retinopathy (DR) afte

293 tic patients with DPN (10 men, 10 women), 20 diabetic patients without DPN (eight men, 12 women), and

294 ness values on both sides compared with both diabetic patients without DPN (P < .001) and healthy con

295 Diabetic patients without DPN had significantly higher s

296 Results Between diabetic patients with and diabetic patients without DPN, mean age (60 years [range

297 Diabetic patients without DR showed a thicker choroid an

298 Overall, 125 diabetic patients without DR were included.

299 patients with DME compared with controls and diabetic patients without retinopathy warrant further po

300 ased treatment for critical limb ischemia in diabetic patients yielded a modest therapeutic effect re